Empirical Financial Services, LLC d.b.a. Empirical Wealth Management
Position in EXEL — Exelixis, Inc.
CIK 1510434
Seattle, WA
Position in EXEL
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$405,310
-$6,823 QoQ
Shares Held
9,450
+0.5% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Empirical Financial Services, LLC d.b.a. Empirical Wealth Management holds $8,046,747 across 13 Biotechnology names. EXEL ranks #6 (5.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
66,223 | $1,639,680 | |
| 2 | INBX |
Inhibrx Biosciences, Inc.
|
22,584 | $1,518,322 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
5,665 | $1,070,968 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
13,851 | $943,667 | |
| 5 | ORKA |
Oruka Therapeutics, Inc.
|
18,229 | $894,131 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
9,450 | $405,310 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
659 | $294,269 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
12,923 | $287,665 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $405,310 | 9,450 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $412,133 | 9,403 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $349,976 | 8,474 | Shares | Sole | 2025-11-10 | |
| 2021-12-31 | $420,257 | 22,990 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $486,008 | 22,990 | Shares | Sole | 2021-11-02 | |
| 2021-06-30 | $419,060 | 23,000 | Shares | Sole | 2021-08-12 | |
| No filing history on record for this holder in this stock. | ||||||